BMDMs were pretreated with neutralizing antibody of IFN-γ (7.5 μg/mL) (Selleck, Houston, USA), inhibitor of BX-795 for TBK1/IKK-ε (2 μM) (Merck KGaA, Germany), inhibitor of Bay-985 for IRF3 (200 nM) (Merck KGaA, Germany), inhibitor of Abrocitinib for JAK1 (200 nM) (Merck KGaA, Germany), inhibitor of Fludarabine for STAT1 (30 μM) (Merck KGaA, Germany) and dimethylsulfoxide (DMSO) as solvent control for corresponding processing time before H37Rv infection. The gene discussed is IFNG; the disease is infection.